WEKO3
アイテム
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes : Post Hoc Analysis of SPARTA Japan
https://tokushima-u.repo.nii.ac.jp/records/2000243
https://tokushima-u.repo.nii.ac.jp/records/2000243d28c5911-692e-400e-acbe-c68a1dd72fb1
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
dt_15_3_705.pdf (1.1 MB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-11-19 | |||||||||||||||||||
| アクセス権 | ||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||
| 関連識別子 | https://doi.org/10.1007/s13300-024-01531-8 | |||||||||||||||||||
| 言語 | ja | |||||||||||||||||||
| 関連名称 | 10.1007/s13300-024-01531-8 | |||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||
| タイトル | ||||||||||||||||||||
| タイトル | Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes : Post Hoc Analysis of SPARTA Japan | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 著者 |
Yabe, Daisuke
× Yabe, Daisuke
× 松久, 宗英
WEKO
415
× Takahashi, Yoko
× Morimoto, Yukiko
× Terauchi, Yasuo
|
|||||||||||||||||||
| 抄録 | ||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||
| 内容記述 | Introduction: The real-world SPARTA Japan study confirmed the effectiveness and safety of the fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) once daily over 6 months in Japanese people with type 2 diabetes (T2D). This post hoc analysis examined the impact of participant characteristics on the achievement of age-defined glycaemic targets with iGlarLixi therapy. Methods: The retrospective, observational SPARTA Japan study included adults with T2D who initiated iGlarLixi. In this analysis, data from insulin-naïve and insulin-experienced participants were separately assessed to compare glycated haemoglobin (HbA1c), body weight and safety outcomes between those who achieved (‘achieved’ group) and those who did not achieve (‘not-achieved’ group) age-defined glycaemic targets after 6 months of iGlarLixi. The not-achieved group was further stratified by whether or not their iGlarLixi dose was increased during treatment. Results: In total, 418 participants were included in this analysis (138 insulin naïve and 280 insulin experienced). Among both insulin-naïve and insulin-experienced participants, those in the achieved group were older and had lower baseline HbA1c than those in the not-achieved group. Compared with the not-achieved group, the achieved group showed significantly greater HbA1c reductions from baseline (in both insulin-naïve and insulin-experienced participants) and significantly greater body weight reductions (in insulin-naïve participants), despite some participants in the not-achieved group receiving significantly higher insulin glargine doses than those in the achieved group. In both insulin-naïve and insulin-experienced participants, the incidence of hypoglycaemia and gastrointestinal-related adverse events was similar in the achieved and not-achieved groups. In a multivariate analysis, glycaemic target achievement was significantly more likely in older individuals and those who lost weight during iGlarLixi treatment. Conclusions: Achievement of age-defined glycaemic targets with iGlarLixi treatment for 6 months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure. |
|||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Fixed-ratio combination | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | iGlarLixi | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Insulin glargine | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Japan | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Lixisenatide | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Real-world data | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Type 2 diabetes mellitus | |||||||||||||||||||
| 書誌情報 |
en : Diabetes Therapy 巻 15, 号 3, p. 705-723, 発行日 2024-02-16 |
|||||||||||||||||||
| 収録物ID | ||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||
| 収録物識別子 | 18696961 | |||||||||||||||||||
| 収録物ID | ||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||
| 収録物識別子 | 18696953 | |||||||||||||||||||
| 出版者 | ||||||||||||||||||||
| 出版者 | Springer Nature | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 権利情報 | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 権利情報 | This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. | |||||||||||||||||||
| EID | ||||||||||||||||||||
| 識別子 | 409204 | |||||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||||
| 言語 | ||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||
